{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:59:29Z","timestamp":1768924769547,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration, National Institutes of Health","doi-asserted-by":"publisher","award":["R01 FD003539"],"award-info":[{"award-number":["R01 FD003539"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Costimulation blockade (CoB)\u2013based immunosuppression offers the promise of improved transplantation outcomes with reduced drug toxicity. However, it is hampered by early acute rejections, mediated at least in part by differentiated, CoB-resistant T cells, such as CD57+PD1\u2212 CD4 T cells. In this study, we characterize these cells pretransplant, determine their fate posttransplant, and examine their proliferative capacity in vitro in humans. Our studies show that CD57+PD1\u2212 CD4 T cells are correlated with increasing age and CMV infection pretransplant, and persist for up to 1 y posttransplant. These cells are replication incompetent alone but proliferated in the presence of unsorted PBMCs in a contact-independent manner. When stimulated, cells sorted by CD57\/PD1 status upregulate markers of activation with proliferation. Up to 85% of CD57+PD1\u2212 cells change expression of CD57\/PD1 with stimulation, typically, upregulating PD1 and downregulating CD57. PD1 upregulation is accentuated in the presence of rapamycin but prevented by tacrolimus. These data support a general theory of CoB-resistant cells as Ag-experienced, costimulation-independent cells and suggest a mechanism for the synergy of belatacept and rapamycin, with increased expression of the activation marker PD1 potentiating exhaustion of CoB-resistant cells.<\/jats:p>","DOI":"10.4049\/jimmunol.2000736","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T17:00:36Z","timestamp":1613581236000},"page":"1668-1676","source":"Crossref","is-referenced-by-count":13,"title":["Functional Characteristics and Phenotypic Plasticity of CD57+PD1\u2212 CD4 T Cells and Their Relationship with Transplant Immunosuppression"],"prefix":"10.1093","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-6549","authenticated-orcid":false,"given":"Brian I","family":"Shaw","sequence":"first","affiliation":[{"name":"Department of Surgery, Duke University , Durham, NC 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn R","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University , Durham, NC 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Stempora","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University , Durham, NC 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University , Durham, NC 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartley","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University , Durham, NC 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-5962","authenticated-orcid":false,"given":"Allan D","family":"Kirk","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University , Durham, NC 27710"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"2025030502024430400_r1","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/ajt.14702","article-title":"An economic assessment of contemporary kidney transplant practice","volume":"18","author":"Axelrod","year":"2018","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2025030502024430400_r3","first-page":"11","article-title":"[Pharmacogenetics of tacrolimus: from bench to bedside?]","volume":"34","author":"Tavira","year":"2014","journal-title":"Nefrologia"},{"key":"2025030502024430400_r4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ckj\/sfx122","article-title":"Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network","volume":"11","author":"Sprangers","year":"2018","journal-title":"Clin. Kidney J."},{"key":"2025030502024430400_r5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2025030502024430400_r6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2025030502024430400_r7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.1496399","article-title":"Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule","volume":"257","author":"Linsley","year":"1992","journal-title":"Science"},{"key":"2025030502024430400_r8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition [Published erratum appears in 2013 Nat. Rev. Immunol. 13: 542.]","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"2025030502024430400_r11","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1111\/ajt.12937","article-title":"CD28 negative T cells: is their loss our gain?","volume":"14","author":"Mou","year":"2014","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2017.04.005","article-title":"mTOR signaling in the differentiation and function of regulatory and effector T cells","volume":"46","author":"Zeng","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"2025030502024430400_r13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.a.22351","article-title":"From \u201ctruly na\u00efve\u201d to \u201cexhausted senescent\u201d T cells: when markers predict functionality","volume":"85","author":"Larbi","year":"2014","journal-title":"Cytometry A"},{"key":"2025030502024430400_r14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ajt.13613","article-title":"CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection","volume":"16","author":"Espinosa","year":"2016","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1681\/ASN.2016010053","article-title":"Premature T cell senescence in pediatric CKD","volume":"28","author":"George","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2025030502024430400_r16","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.14349","article-title":"Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells","volume":"17","author":"Mathews","year":"2017","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r17","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/ajt.14350","article-title":"Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients","volume":"17","author":"Cortes-Cerisuelo","year":"2017","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r18","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/ajt.14353","article-title":"Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function","volume":"17","author":"Adams","year":"2017","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183357","article-title":"Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls","volume":"12","author":"Booiman","year":"2017","journal-title":"PLoS One"},{"key":"2025030502024430400_r20","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1128\/JVI.00438-15","article-title":"Cooperativity of HIV-specific cytolytic CD4 T cells and CD8 T cells in control of HIV viremia","volume":"89","author":"Johnson","year":"2015","journal-title":"J. Virol."},{"key":"2025030502024430400_r21","doi-asserted-by":"crossref","first-page":"8415","DOI":"10.4049\/jimmunol.175.12.8415","article-title":"Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction","volume":"175","author":"Palmer","year":"2005","journal-title":"J. Immunol."},{"key":"2025030502024430400_r22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"2025030502024430400_r23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060186","article-title":"Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection","volume":"8","author":"Hong","year":"2013","journal-title":"PLoS One"},{"key":"2025030502024430400_r24","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20061496","article-title":"PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J. Exp. Med."},{"key":"2025030502024430400_r25","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1128\/JVI.02021-06","article-title":"Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression","volume":"81","author":"Radziewicz","year":"2007","journal-title":"J. Virol."},{"key":"2025030502024430400_r26","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/15256","article-title":"Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance","volume":"5","author":"Li","year":"1999","journal-title":"Nat. Med."},{"key":"2025030502024430400_r27","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/15260","article-title":"Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance","volume":"5","author":"Wells","year":"1999","journal-title":"Nat. Med."},{"key":"2025030502024430400_r28","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/eji.200737583","article-title":"Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance","volume":"37","author":"Wang","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"2025030502024430400_r29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J. Exp. Med."},{"key":"2025030502024430400_r30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r31","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ajt.12712","article-title":"Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors","volume":"14","author":"Kirk","year":"2014","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/ajt.14589","article-title":"IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection","volume":"18","author":"Xu","year":"2018","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r33","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1681\/ASN.2014040399","article-title":"Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts","volume":"26","author":"Loupy","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"2025030502024430400_r34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-6143.2012.04342.x","article-title":"Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion","volume":"13","author":"Lo","year":"2013","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r35","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3389\/fimmu.2019.01844","article-title":"Maintenance of functional CD57+ cytolytic CD4+ T cells in HIV+ elite controllers","volume":"10","author":"Phetsouphanh","year":"2019","journal-title":"Front. Immunol."},{"key":"2025030502024430400_r36","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/TP.0000000000001806","article-title":"mTOR inhibition role in cellular mechanisms","volume":"102","author":"Zaza","year":"2018","journal-title":"Transplantation"},{"key":"2025030502024430400_r37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/acel.12380","article-title":"Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice","volume":"14","author":"Hurez","year":"2015","journal-title":"Aging Cell"},{"key":"2025030502024430400_r38","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1111\/ajt.16121","article-title":"Kidney transplantation using alemtuzumab, belatacept, and sirolimus: five-year follow-up","volume":"20","author":"Schmitz","year":"2020","journal-title":"Am. J. Transplant."},{"key":"2025030502024430400_r39","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"2025030502024430400_r40","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat. Commun."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/206\/7\/1668\/61877509\/ji2000736.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/206\/7\/1668\/61877509\/ji2000736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:06:29Z","timestamp":1741140389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/206\/7\/1668\/7944141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2000736","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,4,1]]}}}